Prognostic and clinicopathological value of fibrinogen-to-albumin ratio in patients with esophageal cancer: a meta-analysis
Abstract Background Fibrinogen-to-albumin ratio (FAR) has been widely examined for its prognostic value in esophageal cancer (EC), although findings across studies have been inconsistent. This meta-analysis aimed to assess the predictive role of FAR in EC. Methods A comprehensive search was conducte...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-06-01
|
| Series: | World Journal of Surgical Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12957-025-03886-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Abstract Background Fibrinogen-to-albumin ratio (FAR) has been widely examined for its prognostic value in esophageal cancer (EC), although findings across studies have been inconsistent. This meta-analysis aimed to assess the predictive role of FAR in EC. Methods A comprehensive search was conducted across Web of Science, Embase, PubMed, and Cochrane Library. The prognostic value of FAR in EC was assessed by pooling hazard ratios (HRs) and 95% confidence intervals (CIs). Additionally, the correlation between FAR and clinicopathological features of EC was evaluated using pooled odds ratios (ORs) and 95%CIs. Results A total of six studies involving 2,616 patients were included. The analysis revealed that a high FAR was significantly associated with poor overall survival (OS) in EC (HR = 1.98, 95%CI = 1.48–2.65, p < 0.001). Furthermore, elevated FAR correlated significantly with male sex (OR = 1.38, 95%CI = 1.09–1.74, p = 0.007), T3–T4 stages (OR = 2.36, 95%CI = 1.93–2.87, p < 0.001), N1–N3 stages (OR = 1.58, 95%CI = 1.32–1.91, p < 0.001), TNM III–IV stages (OR = 2.68, 95%CI = 1.52–4.73, p = 0.001), and tumor length > 3 cm (OR = 2.36, 95%CI = 1.15–4.87, p = 0.020). However, FAR showed no significant association with age (OR = 0.87, 95%CI = 0.48–1.60, p = 0.660), tumor location (OR = 0.98, 95%CI = 0.77–1.25, p = 0.886), or tumor differentiation (OR = 1.09, 95%CI = 0.76–1.56, p = 0.634). Conclusion This meta-analysis highlights that an elevated FAR is a strong prognostic indicator of poor OS in patients with EC. Moreover, high FAR is significantly associated with clinical features indicative of tumor progression and metastasis. |
|---|---|
| ISSN: | 1477-7819 |